Overview

ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pusan National University Hospital
Treatments:
Imatinib Mesylate
Methylprednisolone